2.92

5.19% -0.16

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $2.92, with a volume of 1.12M. It is down -5.19% in the last 24 hours and up +11.88% over the past month. Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Previous Close:

$3.08

Open:

$3.1

24h Volume:

1.12M

Relative Volume:

0.86

Market Cap:

$401.76M

Revenue:

Net Income/Loss:

$-45.44M

P/E Ratio:

-8.3429

EPS:

-0.35

Net Cash Flow:

$-42.28M

1W Performance:

-13.61%

1M Performance:

+11.88%

6M Performance:

+145.38%

1Y Performance:

+62.22%

1-Day Range:

$2.8501

$3.20

1-Week Range:

$2.8501

$3.585

52-Week Range:

$0.765

$4.08

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CMPX's Discussions on Twitter

Compare CMPX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMPX Compass Therapeutics Inc	2.92	401.76M	0	-45.44M	-42.28M	-0.35
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-25	Initiated	Piper Sandler	Overweight
Dec-23-24	Initiated	D. Boral Capital	Buy
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

Feb 20, 2025

Piper Sandler Begins Coverage on Compass Therapeutics (NASDAQ:CMPX) - MarketBeat

Feb 20, 2025

Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Piper Sandler - Defense World

Feb 20, 2025

Feb 19, 2025

Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer - The Globe and Mail

Feb 19, 2025

Piper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight Recommendation - Nasdaq

Feb 19, 2025

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Feb 19, 2025

Piper Sandler Initiates Compass Therapeutics at Overweight -February 19, 2025 at 09:07 am EST - Marketscreener.com

Feb 19, 2025

Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating - TradingView

Feb 19, 2025

Piper Sandler sets $12 target on Compass Therapeutics stock By Investing.com - Investing.com UK

Feb 19, 2025

Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline - TipRanks

Feb 19, 2025

Feb 17, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat

Feb 17, 2025

Chronic Pulmonary Hypertension Market Expected to rise, 2034 | COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market - The Globe and Mail

Feb 17, 2025

Feb 16, 2025

Compass Therapeutics (NASDAQ:CMPX) Trading Down 7.6%Here's Why - MarketBeat

Feb 16, 2025

Feb 14, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 14, 2025

Compass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat

Feb 14, 2025

Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High on Analyst Upgrade - MarketBeat

Feb 14, 2025

Leerink Partnrs Has Strong Outlook for CMPX FY2024 Earnings - MarketBeat

Feb 14, 2025

Feb 13, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by Bleakley Financial Group LLC - Defense World

Feb 13, 2025

Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World

Feb 13, 2025

Feb 12, 2025

Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow - The Globe and Mail

Feb 12, 2025

Organon (OGN) Q4 Earnings Report Preview: What To Look For - The Globe and Mail

Feb 12, 2025

Molson Coors (TAP) Q4 Earnings: What To Expect - The Globe and Mail

Feb 12, 2025

Feb 11, 2025

Procter & Gamble Co: Rising -7.15% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Feb 11, 2025

Jefferies Financial Group Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World

Feb 11, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Feb 11, 2025

FY2024 Earnings Forecast for CMPX Issued By Leerink Partnrs - Defense World

Feb 11, 2025

Feb 10, 2025